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ABSTRAK
Peningkatan kasus infeksi oleh bakteri Gram-negatif multiresisten atau multidrug resistant organism 
(MDRO) menimbulkan problema utama di seluruh dunia karena sudah banyak terjadi resistensi terhadap banyak 
golongan antibiotik. Isolat mutan seperti fluoroquinolon resistance dan β-lactamase resistances sudah banyak 
dijumpai terutama di perawatan intensive care unit (ICU). Pada dua dekade terakhir belum ada penelitian 
pengembangan antibiotik dengan penemuan antibiotik yang baru, sementara resistensi kuman Gram-negatif 
MDRO terhadap antibiotik yang sudah ada semakin meningkat.
Kolistin atau Polymyxin E adalah antibiotik lama telah digunakan sejak tahun 1959 untuk terapi infeksi 
bakteri Gram-negatif MDRO. Kolistin mempunyai efek samping nefrotoksik dan neurotoksik, sehingga 
pemakaiannya kemudian dihentikan dan digantikan antibiotik lain yang efektif tetapi dianggap lebih aman pada 
saat itu. Terjadinya peningkatan kasus infeksi Gram-negatif yang multiresisten (MDRO) terhadap antibiotik yang 
sudah ada, dan belum tersedianya antibiotik alternatif yang memuaskan, maka perhatian para ahli mikrobiologi 
saat ini kembali beralih pada antibiotik lama yang terbukti efektif terhadap bakteri Gram-negatif multiresisten 
yang sudah lama dilupakan yaitu Kolistin, sebagai terapi alternatif  Gram-negatif MDRO. Diharapkan Kolistin 
nantinya dapat berperan menjadi antibiotik masa depan yang penting dan dapat diandalkan untuk pengobatan 
infeksi bakteri Gram-negatif multiresisten, sebagai alternatif antibiotik yang sudah ada selama ini.
Kata kunci: antibiotik, kolistin, Gram-negative, multidrug resistant organism (MDRO).
ABSTRACT
Increasing number of infection cases caused by multiresistant Gram-negative bacteria or multidrug resistant 
organism (MDRO) has become a major problem worldwide since there have been a lot of resistance to many 
classes of antibiotics. Mutant isolates such as fluoroquinolone-resistant and β-lactamase-resistant bacteria have 
been commonly found, particularly in intensive care unit (ICU). During the last two decades, there has been 
no study of developing antibiotics in search of discovering new type of antibiotics; meanwhile, the resistance 
of Gram-negative bacteria or MDRO to antibiotics is increasing.
Colistin or polymyxin E is an old antibiotic, which has been used since 1959 for treating infection caused 
by Gram-negative MDRO. It was revealed that colistin has side effects of nephrotoxicity and neurotoxicity; 
therefore, the use of this antibiotic was stopped and it was replaced by other antibiotics which were effective 
and were considered safer at that time. There is an increasing number of infections with multi-resistant Gram-
negative (MDRO) against the available antibiotics and the availability of alternative antibiotics has not been 
satisfying; therefore, microbiologists are searching back to the old option, which has been proven to be effective 
against multi-resistant Gram-negative bacteria, the old antibiotic that has been long forgotten, i.e. colistin, 
as an alternative treatment against Gram-negative MDRO. It is expected that colistin may have essential and 
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reliable role as future antibiotics for treatment of multi-resistant Gram-negative infections and as an alternative 
of antibiotics that have been available so far.
Key words: antibiotics, colistin, Gram-negative, multidrug resistant organism (MDRO).
INTRODUCTION 
Now, there is an increasing number of 
infections caused by multi-resistant Gram-
negative bacteria or multidrug resistant 
organism (MDRO) such as Pseudomonas 
aeruginosa, Acinetobacter baumannii, Klebsiella 
penumoniae and Stenotrophomonas mallei, 
which produces problems in antibiotic treatment. 
Gram-negative bacteria or MDRO has become 
a major problem worldwide as it develops 
resistance against some antibiotic groups such 
as cephalosporins, quinolones and carbapenems. 
Mutant isolates such as fluoroquinolone-resistant 
and β-lactamase-resistant bacteria have been 
commonly found, particularly in intensive care 
unit (ICU). During the last two decades, there 
has been no study of developing antibiotics in 
search of discovering new type of antibiotics; 
meanwhile, the resistance of Gram-negative 
bacteria or MDRO to antibiotics is increasing.1,2
Colistin is an old antibiotic, which has also 
been known as polymyxin E, was discovered 
by Koyama in 1947 and since 1959, it has 
been used as treatment for infections caused by 
Gram-negative bacteria.3 Groups of Polymyxin 
have been known starting from Polymyxin A to 
Polymyxin E; however, Polymyxin B (PMB) and 
Polymyxin E are those widely used in clinical 
practice, which are also known as colistin. 
At the old time, Polymyxin E or Colistin was 
proven to be effective and showed a very 
good result for treatment of infections caused 
by Pseudomonas aeruginosa, Acinetobacter 
baumannii, Klebsiella penumoniae, Escherichia 
coli, Enterobacter sp, Salmonella sp, Shigella 
sp, and Haemophilus influenzae. The possibility 
of bacterial resistance against the drug at that 
time was still extremely low.1,2 Around 1970 it 
was discovered that colistin had side effects of 
nephrotoxicity and neurotoxicity; therefore, the 
use was subsequently stopped and replaced by 
cephalosporins, amikacin and other effective 
antibiotics, but were considered safer. The use 
of Colistin has been stopped ever since and the 
knowledge and data of research about this drug 
has become very rare or extremely limited.1-3
There is an increasing number of infections 
with multi-resistant Gram-negative (MDRO) 
against the available antibiotics and the 
availability of alternative antibiotics has not 
been satisfying; therefore, microbiologists 
are searching back to the old long-forgotten 
antibiotic, which has been proven to be effective 
against multi-resistant Gram-negative bacteria 
or MDRO, i.e. the Colistin. Studies and data 
collection about Colistin are being continued and 
focused on drug chemical reactions, antibacterial 
activity, mechanism of action, resistance, 
pharmacokinetics, pharmacodynamics and the 
current clinical application. It is expected that 
Colistin will have essential and reliable role as 
future antibiotic for treatment of multi-resistant 
Gram-negative infections and as an alternative 
of antibiotics that have been available so far.2-5
In this manuscript, we will discuss about 
the chemical structure of colistin, including 
pharmacokinetics,  pharmacodynamics, 
mechanism of action, mechanism of resistance, 
indications, contraindications, clinical 
application, side effects and drug toxicity. 
Moreover, we will also discuss about other 
polymyxins and the possibility of using Colistin 
as combined antibiotics for treatment of multi-
resistant Gram-negative (MDRO) infections.
CHEMICAL STRUCTURE
Polymyxin is a lipopeptide antibiotic 
produced by Baccillus sp. Polymyxin is 
categorized into 5 groups, i.e. Polymyxin 
A-E; however, only Polymyxin B (PMB) and 
Polymyxin E (Colistin) that have been widely 
used in clinical practice. Polymyxin A, C and 
D are not used in clinical practice as they are 
extremely toxic. Polymyxin B is produced by 
Bacillus polymyxa; while Polymyxin E (colistin) 
is produced by Bacillus colistinus. Polymyxin is 
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mainly effective for treatment of multi-resistant 
Gram-negative (MDRO) infections such as 
those caused by Pseudomonas aeruginosa, 
Acinetobacter baumannii and Klebsiella 
pneumoniae.6
Both types of Polymyxin, the PMB and 
colistin, are composed of mixed D- and L-amino 
acids forming a decapeptide ring with a tripeptide 
side chain bound to fatty acid (FA) (Figure 1).1 
Different structure of different polymyxin group 
is usually due to the composition of amino acids 
and terminal free-fatty acids. The leucin amino 
acid in Colistin is replaced by D-phenylalanine 
amino acid in PMB7.
Colistin consists of a combination of cyclic 
decapeptide or ring with terminal fatty acid 
chain. Five peptide components are bound to 
free amine component (NH4+), which will have 
cationic characteristic in physiological body 
fluid.1 (Figure 1)
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Figure 1. Chemical structure of Colistin1
The peptide end is hydrophilic; while the 
fatty acid portion is hydrophobic and therefore, 
overall, it has amphipathic characteristic, i.e. 
it can provide fine and stable reaction in polar 
(with electrostatic charge) or non-polar condition 
against the target, i.e. the lipopolysaccharide/LPS 
membrane of the bacteria.6
For clinical applications, there are 2 types of 
chemical structures of colistin. The first is known 
as colistin sulfate in the form of sulfate salt; while 
the second is colistimethate sodium (CMS), 
which is in the form of sodium salt.1 (Figure 2)
Colistin sulfat
Colistimethate Sodium (CMS)
Figure 2. Chemical structure of colistin sulfate and 
colistimethate sodium/CMS1
Colistin was first discovered in oral and 
topical preparation in the form of colistin sulfate 
and it has a strong nephrotoxic and neurotoxic 
effect. Afterwards, some studies were conducted 
to enable modification on its molecular structure 
in order to reduce the toxicity.1 Around the year 
of 1959, colistimethate/CMS was found, which 
is a derivate of less toxic colistin. (Figure 3)
Colistimethate is derived from colistin, which 
is reacted with formaldehyde and bisulphite 
sodium resulting in an additional component 
of –CH2SO3- on all of free amine components 
producing an anionic CMS molecule. Anionic 
colistimethate is an inactive form or a prodrug 
of colistin, which is instable both in vitro and 
in vivo. In a solution with physiological pH, 
colistimethate will immediately change into an 
active form after going through spontaneous 
hydrolysis reaction and releasing the –CH2SO3– 
component into methanesulphonate derivate and 
colistin in the plasma.1
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PHARMACOKINETICS
Pharmacokinetic properties, i.e. absorption, 
distribution and excretion of colistin in the 
body, depends on preparation and route of 
administration.2,4 The oral preparation of 
colistin, i.e. colistin sulfate has poor absorption 
in gastrointestinal tract and it only has local 
bactericidal effect. The half-time of colistin is 
approximately 3.4±1.4 hours and it is excreted 
through glomerular filtration in the kidney.4,5
Colistimethate sodium (CMS) / Colistimethate 
is the form of colistin administered in parenteral 
route (intravenous, intramuscular, intrathecal 
preparation) and through inhalation. In a 
solution, colistimethate sodium or colistimethate 
would be hydrolyzed hydrolysis and forms 
a mixture of methanesulfonate and Colistin 
derivatives in certain conditions depending on 
temperature or time.
In some in vitro studies as quoted by Falagas,4 
we found data that CMS is usually hydrolyzed 
into colistin in human plasma within 1-2 hours 
at 370C.7 The process of sulfomethylation of 
colistin into colistimethate/CMS, which has 
anionic characteristic, will reduce its ability 
to bind to cell membrane wall diminishing its 
toxicity up to 4 times lower; but the process also 
slightly reduces its antibacterial activity.4,5
Colistimethate is tightly bound to membrane 
lipids of cells of various organs such as liver, 
kidney, lung, brain, heart and muscles. The 
release of tissue-bound drug from the cell 
membrane is very slow and can last for more than 
5 days after drug administration. The half-life of 
CMS is 2 hours for intravenous (IV) route and 
inhalation; while for intramuscular (IM) route, 
the half-life is 2.75 - 3 hours. For IV route, 
CMS will be found in the blood approximately 
in 10 minutes and then the concentration 
will be reduced faster compared to IM route. 
Intravenous administration of colistimethate 
has poor distribution in pleural cavity and lung 
parenchyma; however, when it is given through 
inhalation (nebulizer), the results will be better. 
CMS distribution into cerebrospinal fluid is also 
poor. In a case of meningitis due to multiresistant 
Acinetobacter baumanii, the intravenous 
administration of 1 million IU of colistin every 
6 hours can result sufficient penetration of CMS 
into the cerebrospinal fluid (the concentration 
of colistimethate in the cerebrospinal fluid can 
reach 15-25% of the serum concentration of 
colistin).7 A study conducted by Markantonis 
et al, as quoted by Michalopoulos and Falagas,8 
indicates that the intravenous administration of 
colistin has poor and inadequate drug distribution 
and the concentration of drug in the cerebrospinal 
fluid (CSF) is very low, i.e. only about 5-25%. 
Intrathecal administration of CMS will provide 
better and more adequate results than intravenous 
administration of CMS.8 The primary excretion 
of CMS is through spontaneous hydrolysis and 
it is excreted through the kidney. In patients 
with chronic kidney disease, excretion of CMS 
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Figure 3. Chemical structure of colistin (left) and colistimethate sodium (right)1
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will be reduced and the serum concentration 
of CMS derived from spontaneous hydrolysis 
will increase; however, CMS can still be given 
to patients with chronic kidney disease, but the 
dose should be adjusted. Colistin and CMS can 
be excreted efficiently through hemodialysis.7
PHARMACODYNAMICS
Pharmacodynamics is about the effectiveness 
of drug treatment, i.e. the inhibition effect or 
killing effect of bacteria, which is associated 
with the dose, drug interaction and the effect on 
human body.7
The measurement of drug effectiveness in 
vitro can be performed by several methods, such 
as the disc diffusion test according to Kirby Bauer 
method, or by measuring the minimum inhibitory 
concentration (MIC), i.e. the measurement of 
lowest drug concentration that can still inhibit 
bacterial growth after 18-24 hours of incubation. 
Other method that can be performed to evaluate 
the effectiveness of colistin is by performing 
the E test.7
In 2005, the clinical laboratory standard 
institute (CLSI) determined that Colistin 
sulfate (10 ug disc of Colistin sulfate) instead 
of CMS, is used as sensitivity detection test of 
Kirby Bauer method to represent the Colistin, 
since CMS is the prodrug of Colistin, which is 
unstable and it will cause difficult interpretation 
on test results.2 The sensitivity test method using 
disc diffusion test of Kirby Bauer through the 
utilization of 10 µg colistin disc for Pseudomonas 
aeruginosa isolates shows positive results when 
the inhibition zone around the disc is ≥11 mm 
and it is considered as resistant when the zone of 
inhibition is ≤10 mm.9 However, there is no CLSI 
recommendation (2014) on the use of Kirby 
Bauer method for Acinetobacter baumannii 
isolates.9
According to CLSI recommendation as 
quoted by Kwa,7 the susceptibility testing 
for Colistin is better performed by minimum 
inhibitory concentration (MIC) method. The 
rational is that disc diffusion test by Kirby 
Bauer method for colistin has a very high 
level of interpretation error and therefore, 
MIC method is more preferable.7 The CLSI 
recommendation for sensitivity test of P. 
aeruginosa with MIC method suggests that it 
is considered sensitive when the MIC is ≤2 ug/
mL and it is considered resistant when the MIC 
is ≥8 ug/mL; while for Acinetobacter baumannii 
isolates, the MIC of ≤2 ug/mL is considered 
sensitive and MIC of ≥4 ug/mL is considered as 
resistant. There has been no recommendation 
of CLSI for Enterobacteriaceae.9 Based on its 
pharmacodynamics profile, the drug inhibits the 
activity of Gram-negative bacteria at an effective 
concentration or having concentration/dose 
dependent characteristics.5,7
DOSE AND ROUTES OF ADMINISTRATION
Intravenous administration of Colistin 
(Colistimethate sodium/CMS), which is 
recommended in the United States, is 2.5 – 5 
mg/kg BW/day divided into 2-4 doses (1 mg 
CMS = 12,500 IU).
The dose can be given to adults with normal 
kidney function. In England, the recommended 
intravenous dose of colistin is 4-6 mg/kg BW/day 
divided in 3 doses for adults or for children with 
BW of ≤60 kg. For those with BW of >60 kg, the 
recommended dose is 80-160 mg every 8 hours.5 
Falagas.5 recommends intravenous CMS dose 
of 729 mg/kgBW/day in 3 divided doses. For 
severe Gram-negative MDRO infection case, the 
recommended dose for colistimethate treatment 
is 160 mg/8 hours. The recommended duration 
of treatment for pneumonia or bacteremia cases 
is 14 days.5 Modification on total daily dose 
must be regulated and adjusted for patients with 
kidney disorder. Intravenous colistin can be 
given with recommended dose adjustment, i.e. 
when the serum creatinine level is 1.3-1.5 mg/
dL the dose should be 160 mg/12 hours; when 
the serum creatinine level is 1.6 – 2.5 mg/dL, 
the dose should be given at 160 mg/24 hours and 
if the serum creatinine level is ≥2.6 mg/dL, the 
given dose is 160mg/36 hours. There is no data 
on modified dose that must be given to patients 
with hepatic failure. In patients with obesity, the 
dose adjustment is still calculated based on dose 
for ideal body weight.5
In addition to intravenous administration, 
colistimethate can be administered through 
intramuscular / IM route;  however,  IM 
administration is not recommended as it can 
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cause very painful effect on injection site. Around 
1970, there were efforts to reduce the pain caused 
by IM administration by giving local anesthetics 
of dibucaine hydrochloride; however now, this 
procedure has been abandoned. Combination of 
colistimethate and anesthetics has been utilized 
more commonly for eye and ear drop preparation 
and eye ointment for treatment of infections 
caused by Gram-negative MDRO such as 
Pseudomonas aeruginosa.5 The recommended 
dose of CMS for inhalation administration is 
40 mg/12 hours for patients with BW ≤40 kg 
and 80 mg/12 hours in patients with BW >40 
kg. The dose of inhalation administration of 
colitin aerosol can be increased up to 160 mg/8 
hours for recurrent lung infections. Inhalation 
administration or nebulation can sometimes 
causes hyper-reactive bronchoconstriction. It has 
been reported that the condition can be managed 
by inhalation administration of β2 agonist agent 
first before commencing the colistin inhalation 
in order to prevent bronchoconstriction.5
There is very little number of data has 
been reported on the intrathecal administration 
of colistimethate/CMS for cerebral infection 
or intraventricular administration of colistin 
against Gram-negative MDRO bacteria. 
Michalopoulos and Falagas.5 reported the 
dose of intrathecal administration ranged from 
3.5 to 10 mg given once daily for 2 cases of 
meningitis with multi-resistant Gram-negative 
bacteria in an ICU and they found a relatively 
adequate treatment effect. A study conducted 
by Michalopoulos and Falagas also reported 2 
cardiac cases (postneurosurgical ventriculitis) 
using intraventricular administration of colistin 
dose as many as 5-20 mg/day divided in 2 doses 
and they found improvement.5
Colistin sulfate is usually given by oral 
administration. It has local effect for treatment 
of diarrhea in enterocolitis, bacillary dysentery, 
particularly in infants and children. The dose for 
children with body weight of 0-15 kg ranged from 
0.25 to 0.5 million IU is given 3 times daily; while 
for those with 15-30 kg, the drug is administered 
with a dose ranged from 0.75 - 1.5 million IU 
given 3 times daily. The adult dose is 1.5 – 3 
million IU given 3 times daily. In addition to oral 
preparation, colistin sulfate is also commonly 
used in topical, eye-drop and ear-drop preparation; 
particularly when there is a suspicion of an 
infection caused by Pseudomonas aeruginosa or 
Acinetobacter baumannii.3 The administration 
of colistin sulfate must be monitored closely and 
it should be considered as the last alternative 
treatment when the sensitivity test shows no more 
sensitivity for treatment using other antibiotics.5
MECHANISM OF ACTION
Colistin or also known as Polymyxin E has 
been known as an old class antibiotic, which 
are active against some pathogenic multi-
resistant Gram-negative bacteria including 
Pseudomonas aeruginosa, Acinetobacter 
baumannii and Klebsiella pneumoniae that 
resistant to carbapenem treatment.1
Mechanism of action of colistin against 
Gram-negative bacteria is mainly targeted 
on lipopolysaccharide (LPS) of the outer 
membrane (Figure 4). Lipopolysaccharides are 
the component of Gram-negative bacteria cell 
wall, which consist of double lipid layer (lipid 
bilayer) and polysaccharides containing negative 
charges; moreover, those are stabilized by 
bivalent cations, especially calcium (Ca++) and 
magnesium (Mg++). Peptidoglycan (PG) layer is 
located between the outer and inner membranes. 
Colistin has 5 components of peptides and 5 
components of amines with polycationic end, 
which can compete and substitute the position of 
calcium and magnesium ion on the bacterial lipid 
Figure 4. Mechanism of action of colistin1
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LPS membrane.
The Colistin peptide end, which has 
hydrophilic characteristic and positive charge, 
will have a strong electrostatic bound with the 
negatively charged bacterial LPS membrane.1,4,5 
The colistin fatty-acid end with hydrophobic and 
non-polar nature (the lypophylic end) will also 
bind to LPS lipid layer and strengthen the peptide 
binding with LPS. The binding between colistin 
peptide and LPS will lead to derangement of 
the whole LPS structure, reducing membrane 
integrity, increasing membrane permeability, 
causing leakage of cell contents and eventually 
cell death.1,5
CMS is an anionic drug and therefore, its 
ability to bind with the negatively charged LPS 
membrane is lower than colistin. The condition 
is consistent with the role of CMS as a prodrug, 
which begins its bactericidal effect after changing 
its structure into Colistin.1,3,4
MECHANISM OF RESISTANCE
The prevalence of resistance to colistin is 
relatively low and the data is scarce; probably, 
because the drug is rarely used for treatment. Ko 
as also quoted by Yahaf,4 identified the presence 
of resistance of Acinetobacter baumannii, 
Pseudomonas aeruginosa and Klebsiella 
pneumoniae against Colistin through gene 
analysis conducted in Korea; however no 
further data was found. Many theories have 
been proposed about the general mechanism 
of developing resistance, such as through 
modification of LPS outer membrane structure, 
i.e. the bacteria change the negatively charged 
phosphate component of LPS into a neutral 
component, which weaken the binding of 
polymyxin with LPS wall. Moreover, the 
mechanism of efflux pump may also have role 
in developing mechanism of bacterial resistance 
against colistin.4
It is assumed that the mechanism of resistance 
for Pseudomonas aeruginosa against polymyxin 
is involving protein on LPS of outer membrane 
(oprH) formed by the bacteria, which has 
polycationic characteristic and can substitute 
the position of calcium and magnesium ions as 
the stabilizer of LPS wall. The binding between 
oprH and LPS wall is so strong that polymyxin 
may not penetrate and causing damage to LPS.1
Colistin must be administered according to 
its indication, based on the results of sensitivity 
test and should be closely monitored with 
adequate dose since inappropriate and irrational 
administration of colistin may induce cross 
resistance with polymyxin B developing the 
emergence of hypervirulent new strain in the 
future.7,10
It is assumed that Acinetobacter baumannii 
develops mechanism of resistance since the 
bacteria has rapid and easy adaptation and 
can change into resistant phyenotype when 
it is exposed to polymyxin. Another theory 
of polymyxin resistance to Acinetobacter 
baumannii is that there is a sub-population of 
polymyxin-resistant strain; therefore, initially 
the detection using MIC method gives sensitive 
results, but the result will be resistant when we 
repeat the resistance culture procedure.1
INDICATIONS
The indication for colistin administration 
is for treatment of infection caused by Gram-
negative bacteria, which have been resistant to 
many other antibiotics (MDRO) and it has been 
confirmed by antibiotic sensitivity test.5
In vitro, colistin has been demonstrated 
to be effective for many infections caused by 
Gram-negative bacillary bacteria. It is effective 
against infections caused by Enterobacteriaceae 
group such as those caused by Escherichia 
coli, Citrobacter sp, and Morganella morganii. 
The activity of this antibiotic is also effective 
against Gram-negative bacteria, which is 
commonly multiresistant (MDRO), such as 
Pseudomonas aeruginosa, Escherichia coli, 
Enterobacter sp, Klebsiella sp and Bordetella 
pertussis.2 According to CLSI, the in vitro 
activity is relatively good against multi-resistant 
Gram-negative bacteria such as Pseudomonas 
aeruginosa and Acinetobacter baumannii and 
it can be said that the treatment is sensitive for 
both types of bacteria when the MIC is ≤2 mg/L.9
Not all of Gram-negative bacteria is 
sensitive to Colistin. Pathogenic bacteria such 
as Neisseria sp (including meningococci and 
gonococci), Stenotrophomonas mallei, Proteus, 
Serratia, Providencia, Moraxella catarrhalis, 
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Helicobacter pylori, Edwarsiella sp, Brucella 
sp and Burkholderia cepacia are commonly 
resistant to Colistin.2 The susceptibility of 
Campylobacter sp to Colistin has a wide range 
of variation.2
Gram-positive bacteria, both bacillary or 
coccus, are usually resistant to Colistin. Colistin 
cannot be used for treatment against infections 
caused by Gram-positive bacteria, all coccus, 
vibrio and anaerobic bacteria.2
CONTRAINDICATIONS
Contraindications for colistin are patients 
with myasthenia gravis and hypersensitivity to 
polymyxin. Colistin is not recommended for 
women during their pregnancy and lactation 
period. For patients with kidney failure, colistin 
can still be administered with dose adjustment 
and close monitoring. Although there are some 
studies on effectiveness and toxicity of various 
treatment of colistin, but Falagas5 suggests that 
the proportion of patients treated with colistin 
and then had kidney disorder (nephrotoxicity) is 
not as many as the number of previous reports. 
However, it must be used carefully and consistent 
with the indications.5 Colistin co-administration 
with antibiotics which have nephrotoxicity effect 
such as aminoglycosides is not recommended.1,5
Colistin should be administered based on 
the results of sensitivity test to minimize the 
development of resistance due to excessive use.1,5
CLINICAL APPLICATIONS
Colistin has become an alternative treatment 
for bacteremia cases or sepsis and ventilator 
associated pneumoniae (VAP) cases in ICU. 
There are some clinical applications of Colistin, 
such as for urinary tract infections, meningitis, 
osteomyelitis, infections of gastrointestinal tract, 
skin and soft tissue infections or abscess and eye 
and ear infection.8
Sepsis/Bacteremia
A study conducted by Markoudi in ICU, 
as quoted by Falagas,8 found a good clinical 
response for sepsis and septic shock cases caused 
by K. pneumoniae MDRO by giving 9 million 
IU of intravenous CMS/day (2.5 mg/kg BW/day) 
divided in 3 doses.8
Pulmonary Infections
In patients with nosocomial pneumonia 
such as those with hospital acquired pneumonia/
HAP or ventilator associated pneumonia/VAP 
caused by Gram-negative MDRO including P. 
aeruginosa and A. baumannii, the administration 
of Colistin in the form of CMS inhalation 
can be used as an alternative treatment for 
VAP. The effective daily dose is 3.2 million 
IU of CMS divided in 3 doses for 14 days of 
treatment.8 Co-administration in combination 
with meropenem, piperacillin, tazobactam and 
ampicillin sulbactam results in a recovery rate 
up to 75.6%.8 Colistin in the form of CMS 
can be more effective with inhalation route of 
administration for patients with pulmonary cystic 
fibrosis.4,8 It has been reported that the drug is less 
likely to be resistant than Tobramycin.4
Urinary Tract Infections
A study conducted by Patricia reported that 
the use of colistin in the form of intravesical CMS 
for treatment of persistent urinary tract infections 
(UTI) caused by Acinetobacter baumannii. When 
3.5 mg/kgBW of colistin was diluted in 500 cc 
of NaCl and is given as an irrigation for 7 days, 
the symptoms of UTI diminished on the 2nd day 
of irrigation treatment. Results of urine culture 
taken within 10 days after the irrigation treatment 
has been completed showed negative results.11
Meningitis
For meningitis cases caused by Gram-
negative MDRO (such as multiresistant 
Acinetobacter baumannii), the absorption of 
intravenous CMS into cerebrospinal fluid is 
poor (the concentration of colistimethate in 
cerebrospinal fluid is only 15-25% of serum 
level).7 A study conducted by Karabinis, as 
quoted by Falagas8, demonstrated that for 
meningitis cases which showed no response to 
intravenous CMS, intrathecal administration of 
CMS at the dose of 3.75-10 mg/day for 14 days 
could be considered and it was quite successful. 
There are very few data on meningitis cases 
with colistin treatment and further treatment is 
still necessary.8
Osteomyelitis
It has been reported that a case of osteomyelitis 
caused by Acinetobacter baumannii MDRO 
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infection was getting better after intravenous 
bolus injection of 80 mg CMS followed with 
480 mg drip intravenous CMS for 24 hours. 
The treatment was performed with a careful 
monitoring on kidney function and doctors 
must always aware on the potential toxicity of 
the drug.2
Gastrointestinal Tract Infections
For gastrointestinal tract infections caused 
by Gram-negative MDRO bacteria, oral 
administration of colistin (colistin sulfate) in 
the form of tablets or syrup can be considered. 
Oral administration of colistin provides a good 
local effect on gastrointestinal tract as it has 
poor intestinal absorption and it is used mainly 
for treatment of diarrhea in children.4 The oral 
administration for intestinal infection must 
be carefully monitored with appropriate dose 
considering the toxic effects. The administration 
of colistin sulfate must be executed based on 
indication and it is not recommended for empiric 
use in diarrhea cases due to its toxic effects.5
Skin and Soft Tissue Infections
Colistin in the form of colistin sulfate can 
be given as topical preparation. The drug must 
be carefully administrated and consistent with 
the indication, i.e. for infections caused by 
Gram-negative MDRO bacteria, but it is not 
recommended for empiric treatment.5
Eye and Ear Infections
For eye and ear infections, especially 
those infections caused by Gram-negative 
MDRO bacteria, colistin sulfate has been used 
frequently in the form of ointment or eye and 
ear drop preparation. There is still no data on 
the administration of colistin for endophtalmitis 
cases.5-7
SIDE EFFECT AND TOXICITY
The widely known side effect of the drug is 
nephrotoxicity and neurotoxicity; however, both 
of side effects are reversible and rapidly diminish 
when the drug is stopped.
Risk factors that affect the nephrotoxicity 
are elderly age, history of previous renal 
insufficiency, the presence of combination 
treatment with other nephrotoxic antibiotics.1,12 
Clinical manifestations of the nephrotoxic effect 
that can be found are hematuria, proteinuria, 
oliguria, acute tubular necrosis (ATN) and 
reduced creatinine clearance and increased ureum 
and creatinine serum level.1,6 The increased 
levels of ureum and creatinine usually develop 
within approximately 4 days after commencing 
the colistin treatment.1 After the treatment is 
stopped, the creatinine serum level is usually 
still high for about 2 weeks and it will be back 
to normal within 3-9 weeks.1 The incidence rate 
of nephrotoxicity with colistin treatment that has 
been reported is 20.2% out of 317 cases. Another 
study reported that in patients with cystic fibrosis 
who were treated colistin, there was renal 
dysfunction due to potentiation effect since the 
colistin was administered in combination with 
aminoglycoside. The study reported that the 
administration of colistin alone or in combination 
with other non-nephrotoxic antibiotic did not 
cause increased incidence of nephrotoxic effect. 
Therefore, treatment using colistin must be 
administered along with close monitoring on 
kidney function, route of administration and 
should avoid combination treatment with other 
antibiotics that may cause nephrotoxic side 
effects. The current data in 2013 showed that the 
prevalence of nephrotoxicity of colistin treatment 
ranged between 11 and 24%.1 Further studies are 
necessary, which will study about the standard 
procedure of monitoring side effect and optimal 
dose for effective and safe colistin treatment in 
order to avoid nephrotoxicity.12
The side effect of neurotoxicity manifests 
in the form of dizziness, lethargy, facial and 
peripheral paraesthesia, vertigo, vision loss, 
ataxia, neuromuscular junction block, which may 
lead to respiratory failure or apnea.
In patients who are sensitive, inhalation 
administration can cause mild bronchoconstriction. 
Intraventricular and intrathecal administration 
of colistin, particularly in high dose, must be 
closely monitored as it can cause seizure.5 Other 
side effects that can be found during colistin 
treatment are hypersensitivity reaction, skin rash, 
urticarial, pruritus and muscle weakness of all 
body parts and mild gastrointestinal disorder. 
Several studies suggest that neurotoxic effects 
are more likely found in patients with cystic 
fibrosis.1 It has been reported that the incidence 
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of neurotoxicity during colistin treatment is 
approximately 7% with main symptom of 
paraesthesia.1 The incidence of allergic reaction 
is about 2%.1,5
A study conducted by Tamma demonstrated 
that 22% out of 229 cases of infection in children 
treated with colistin had both nephrotoxicity 
and neurotoxicity, but the side effects were 
reversible and diminished when the treatment 
was stopped.13
COMBINATION WITH OTHER ANTIBIOTICS
Some clinical trials associated with the 
combined activity of colistin and other synergetic 
antibiotics have been performed. Colistin which 
is administered in combination treatment can 
reduce the therapeutical colistin dose to optimal 
dose; therefore, the treatment is still effective 
with reduced side effects.14 In a study of 53 
patients with cystic fibrosis and exacerbation 
of chronic pulmonary infections caused by 
Pseudomonas aeruginosa, it demonstrated 
that combined colistin treatment with anti-
pseudomonal antibiotics such as azlocillin, 
piperacillin, aztreonam, ceftazidime, imipenem, 
ciprofloxacin was actually more effective 
compared to monotherapy colistin treatment.3,5,14
A study conducted by Lee indicated 
that combination treatment using colistin 
and carbapenem, tigecycline or rifampin 
for Klebsiella pneumoniae Carbapenemase 
(KPC) case was quite effective compared to 
monotherapy colistin or polymyxin treatment.15
The synergetic activity of colistin with 
ceftazidime in 2 cases of Pseudomonas aeruginosa 
MDRO infection has also been reported. The 
combination of colistin with rifampicin and 
amikacin has also develop synergetic effect in 
vitro and it has been proven to be effective and 
successful for immunocompromised patients 
with multiple abscess in lungs, perineum and 
gluteus caused by Pseudomonas aeruginosa. 
Combined colistin and rifampicin treatment has 
also provide synergetic antibactericidal effect for 
infections caused by Pseudomonas aeruginosa 
MDR.5
Combined colistin and sulbactam, imipenem/ 
carbapenem, or tigecycline treatment provide 
synergetic effect and it can be considered as a 
treatment for infections caused by Acinetobacter 
baumannii MDRO.16
OTHER POLYMYXINS
In addition to colistin, which is also known as 
Polymyxin E, only Polymyxin B (PMB) has been 
widely recognized and used in clinical practice. 
The main difference between Polymyxin B 
and colistin is on their molecular structure, i.e. 
Polymyxin B contains phenylalanine. Polymyxin 
B has similar mechanism of action and resistance 
with colistin. Compared to Polymyxin B, 
colistin has better therapeutical effect against 
Pseudomonas aeruginosa, Salmonella sp 
and Shigella sp but less toxic compared to 
Polymyxin B. Although it has the same route of 
administration with colistin, but polymyxin B 
has been produced largely and mainly for topical 
use as eye or ear drop.5 A study by Yahaf in Italy 
found 64 cases of severe sepsis or septic shock in 
intraabdominal infections, which had emergency 
surgery and the mortality rate was reduced after 
Polymyxin B treatment.4
The half-life of polymyxin B is longer than 
colistin. It has a very strong binding with protein 
serum, i.e. 98.4% at 370C. There is very limited 
data on the use of Polymyxin B in clinical 
practice because although it is the most potent 
drug of all polymyxin groups, but it also has 
greater nephrotoxic effect compared to CMS. 
The drug can cause derangement of tubular 
cells, which may lead to acute tubular necrosis. 
A study conducted by Vincent5 as quoted by 
Falagas8 demonstrated that after intramuscular 
administration of Polymyxin B, the highest 
concentration in blood was reached in 2 hours 
and the half-life was approximately 6 hours.5
The drug has started to be used as inhalation 
therapy for pneumonia and tracheobronchitis, 
particularly for those infections caused by P. 
aeruginosa (nosocomial pneumonia) and it has 
a good effect and no side effect has ever been 
found. The dose for polymyxin B inhalation is 
500,000 IU, given twice daily for 14 days.17
The possibility of intrathecal and intravenous 
administration of Polymyxin B as a treatment for 
central nervous system infection still needs further 
studies. Combination treatment with imipemem, 
azithromycin or rifampicin provides synergetic 
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effect in vitro.15 Until now, Polymyxin B is only 
used as alternative treatment, particularly for 
Gram-negative infections, which is resistant to 
carbapenem (MDRO), but it is not recommended 
for empirical treatment or prophylaxis.17
FUTURE APPLICATIONS
Further studies on pharmacokinetics and 
pharmacodynamics of polymyxin are necessary, 
particularly colistin, including the development 
of its formulation, a consensus on optimal 
daily dose, route of administration and interval 
dose, studies on evaluation of drug toxicity, 
mechanism of resistance to colistin. Moreover, 
further studies should also be performed on 
effectiveness and safety of colistin inhalation 
for nosocomial pneumonia caused by Gram-
negative MDRO bacteria and to determine the 
most effective combination treatment of colistin 
and other antibiotics.16
Until now, colistin is not recommended for 
empirical treatment; although the combination 
with other antibiotics such as rifampicin and 
carbapenem is quite effective, but it is still a 
difficult decision to recommend such treatment 
as most of studies are in vitro and there is only 
few in vivo data. Inhalation administration of 
CMS can be considered as additional treatment 
of systemic antibiotic therapy for VAP cases; 
however, it has not been always successful in 
clinical practice.16
CONCLUSION
Treatment with polymyxin, particularly 
colistin has been reintroduced to clinical practice 
against multi-resistant Gram-negative bacteria 
(MDRO). For therapy, colistin is recommended 
for severe infection cases caused by Gram-
negative MDRO, but it should be given in 
combination treatment with other antibiotics and 
it is not recommended for empirical treatment 
and monotherapy. The recommended duration 
of treatment for pneumonia or bacteremia is 14 
days. Physicians should aware of possible side 
effects of Colistin, particularly nephrotoxicity 
and neurotoxicity. It is recommended to have 
an evaluation on kidney function, i.e. creatinine 
serum level every other day to provide close 
monitoring on the possibility of nephrotoxic 
effect.
Rational treatment of Colistin must be 
closely monitored so that pan-resistant strains 
will not be developed. Continuous studies 
and further knowledge on the structure and 
activity of colistin, its pharmacokinetics, 
pharmacodynamics and optimal combination 
treatment have made colistin as a promising 
alternative antibiotic treatment against Gram-
negative bacteria MDRO in the future.
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